CN113440468A - 美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法 - Google Patents
美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法 Download PDFInfo
- Publication number
- CN113440468A CN113440468A CN202110942740.7A CN202110942740A CN113440468A CN 113440468 A CN113440468 A CN 113440468A CN 202110942740 A CN202110942740 A CN 202110942740A CN 113440468 A CN113440468 A CN 113440468A
- Authority
- CN
- China
- Prior art keywords
- skin
- conditioner
- whitening
- parts
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 108
- 238000005282 brightening Methods 0.000 title claims abstract description 53
- 150000001875 compounds Chemical class 0.000 title claims abstract description 52
- 239000002884 skin cream Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 230000001681 protective effect Effects 0.000 claims abstract description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 16
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 16
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 9
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 9
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims abstract description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 8
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims abstract description 8
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 8
- 108010087806 Carnosine Proteins 0.000 claims abstract description 8
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 8
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000458 allantoin Drugs 0.000 claims abstract description 8
- 229940036350 bisabolol Drugs 0.000 claims abstract description 8
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 8
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 8
- 229940044199 carnosine Drugs 0.000 claims abstract description 8
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 8
- 229910003472 fullerene Inorganic materials 0.000 claims abstract description 8
- 229960003258 hexylresorcinol Drugs 0.000 claims abstract description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 6
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 6
- 239000011570 nicotinamide Substances 0.000 claims abstract description 6
- 229940035423 ethyl ether Drugs 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 26
- 206010040829 Skin discolouration Diseases 0.000 claims description 20
- 230000008439 repair process Effects 0.000 claims description 20
- 239000002562 thickening agent Substances 0.000 claims description 20
- 230000004224 protection Effects 0.000 claims description 19
- 239000003906 humectant Substances 0.000 claims description 18
- 230000001804 emulsifying effect Effects 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 13
- 239000000516 sunscreening agent Substances 0.000 claims description 13
- 239000000811 xylitol Substances 0.000 claims description 13
- 229960002675 xylitol Drugs 0.000 claims description 13
- 235000010447 xylitol Nutrition 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000003974 emollient agent Substances 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- -1 liquorice flavonoid Chemical class 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 239000006177 biological buffer Substances 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000005070 sampling Methods 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 3
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 claims description 3
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 claims description 3
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 3
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- 241000167550 Centella Species 0.000 claims description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 240000008632 Cota tinctoria Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 241000972672 Phellodendron Species 0.000 claims description 3
- 240000001341 Reynoutria japonica Species 0.000 claims description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 229960005193 avobenzone Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229940116229 borneol Drugs 0.000 claims description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 229940119217 chamomile extract Drugs 0.000 claims description 3
- 235000020221 chamomile extract Nutrition 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229960001031 glucose Drugs 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 150000008131 glucosides Chemical class 0.000 claims description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 3
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004881 homosalate Drugs 0.000 claims description 3
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 3
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000601 octocrylene Drugs 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229940070721 polyacrylate Drugs 0.000 claims description 3
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 229940098760 steareth-2 Drugs 0.000 claims description 3
- 229940100458 steareth-21 Drugs 0.000 claims description 3
- 235000020238 sunflower seed Nutrition 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 235000019149 tocopherols Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- KZVAAIRBJJYZOW-VPENINKCSA-N (2r,3r,4s)-2-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC[C@H]1OC[C@H](O)[C@H]1O KZVAAIRBJJYZOW-VPENINKCSA-N 0.000 claims 1
- 244000146462 Centella asiatica Species 0.000 claims 1
- 235000004032 Centella asiatica Nutrition 0.000 claims 1
- 240000004534 Scutellaria baicalensis Species 0.000 claims 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims 1
- 235000006468 Thea sinensis Nutrition 0.000 claims 1
- 229940083987 anhydroxylitol Drugs 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000002633 protecting effect Effects 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 238000009776 industrial production Methods 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 66
- 230000000694 effects Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 239000002537 cosmetic Substances 0.000 description 17
- 230000003020 moisturizing effect Effects 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 241000252212 Danio rerio Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 241000700198 Cavia Species 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003061 melanogenesis Effects 0.000 description 4
- 235000021283 resveratrol Nutrition 0.000 description 4
- 229940016667 resveratrol Drugs 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 2
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940092665 tea leaf extract Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种美白亮肤的皮肤调理剂复合物和新的护肤霜,包括按照重量份剂的以下组分:美白亮肤调理剂2‑8份,防护调理剂2‑8份,修复调理剂0.0005‑1份;美白亮肤调理剂包括烟酰胺、己基间苯二酚和肌肽;防护调理剂包括VC乙基醚、尿囊素、甘草酸二钾、提取复配物canlmyang、富勒烯、纳米金和红没药醇;修复调理剂包括提取复配物百倍舒。该美白亮肤的皮肤调理剂复合物的具体成分包括美白原料、天然原料以及中药复配物,这些组分协同作用,能够同时实现美白、防护及修复三重功能。本发明还公开了一种新的护肤霜的制备方法,流程简便,对设备、操作人员要求不高,便于实现工业化生产。
Description
技术领域
本发明涉及护肤品技术领域,尤其涉及一种美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法。
背景技术
成为“白富美”是很多女性的梦想,但近年来,美白化妆品问题频发,给很多女性美白之梦蒙上阴影。此外,国家食品药品监督管理总局发布的《关于调整化妆品注册备案管理有关事宜的通告》,将美白化妆品纳入特殊用途化妆品进行管理。这一转变对于占据我国护肤化妆品市场30%份额的美白产品的影响不言而喻,业界预计将引发我国美白市场的新一轮变局。对人体健康无害,又具有美容保健作用护肤化妆品已经成为研究热点。
近些年美白化妆品中有关皮肤黑色素成因、美白机理、美白效果的评价、美白剂的选择等方面的研究不断深入,美白概念也逐步发生了改变,由单一物理涂抹转向化妆品中添加天然活性美白剂,再到如今将美白、防护及修复功能于一体的美白理念逐渐成为趋势,逐步受到消费者认可。寻找对人体健康无害和开发多个功能兼备的护肤化妆品,已经成为亟需解决的问题。
发明内容
为了克服现有技术的不足,本发明的目的之一在于提供一种美白亮肤的皮肤调理剂复合物,能够同时实现美白、防护及修复三重功能。
本发明的目的之二在于提供一种新的护肤霜,采用目的之一的美白亮肤的皮肤调理剂复合物为活性成分,能够同时实现美白、防护及修复三重功能。
本发明的目的之三在于提供一种新的护肤霜的制备方法,流程简便,对设备、操作人员要求不高,便于实现工业化生产。
本发明的目的之一采用如下技术方案实现:
一种美白亮肤的皮肤调理剂复合物,包括按照重量份剂的以下组分:美白亮肤调理剂2-8份,防护调理剂2-8份,修复调理剂0.0005-1份;所述美白亮肤调理剂包括烟酰胺、己基间苯二酚和肌肽;所述防护调理剂包括VC乙基醚、尿囊素、甘草酸二钾、提取复配物canlmyang、富勒烯、纳米金和红没药醇;所述修复调理剂包括提取复配物百倍舒。
进一步地,所述提取复配物canlmyang为积雪草提取物、虎杖提取物、黄芩提取物、茶叶提取物、光果甘草提取物、母菊花提取物和迷迭香叶提取物形成的复配物。
进一步地,所述提取复配物百倍舒为黄柏提取物、蛇床子提取物、五倍子提取物、金黄洋甘菊提取物、积雪草提取物、甘草类黄酮和冰片形成的复配物。
进一步地,所述美白亮肤调理剂还包括表面活性剂和抗菌剂;所述防护调理剂还包括生物缓冲剂。
进一步地,所述表面活性剂和抗菌剂为二辛基醚、亚油酸和苯氧乙醇的复配物;所述生物缓冲剂为羟乙基哌嗪乙烷磺酸和水的复配物。
进一步地,所述美白亮肤调理剂包括烟酰胺1-3.5份、己基间苯二酚0.25-1份、肌肽0.1-0.3份、表面活性剂和抗菌剂1-3份。
进一步地,所述防护调理剂包括VC乙基醚0.5-3份、尿囊素0.1-1份、甘草酸二钾0.1-1份、提取复配物canlmyang0.05-0.1份、生物缓冲剂0.3-0.8份、富勒烯0.00001-0.0001份、纳米金0.00005-0.0001份和红没药醇0.1-1份。
进一步地,所述修复调理剂包括提取复配物百倍舒0.0005-0.001份。
本发明的目的之二采用如下技术方案实现:
一种新的护肤霜,包括目的之一所述的美白亮肤的皮肤调理剂复合物。
进一步地,所述新的护肤霜包括按照重量份计的以下组分:溶剂50-70份;保湿剂10-20份;润肤剂5-15份;增稠剂1.5-8份;乳化剂1.5-8份;防晒剂0.1-1份;抗氧剂0.1-1份;螯合剂0.01-0.5份;美白亮肤调理剂2-8份,防护调理剂2-8份,修复调理剂0.0005-1份。
进一步地,所述溶剂包括水;所述保湿剂包括丁二醇、甘油聚醚-26、己二醇、乳酸和木糖醇复配保湿剂;所述润肤剂包括植物角鲨烷和聚二甲基硅氧烷;所述增稠剂包括鲸蜡硬脂醇、汉生胶、聚丙烯酸酯交联聚合物-6和G57增稠剂;所述乳化剂包括硬脂醇聚醚-2和硬脂醇聚醚-21;所述抗氧剂包括对羟基苯乙酮;所述螯合剂包括EDTA-2NA。
进一步地,所述木糖醇复配保湿剂为木糖醇基葡糖苷、脱水木糖醇、木糖醇和葡萄糖的复配物;所述G57增稠剂为聚丙烯酸钠、C18-21烷和十三烷醇聚醚-6的复配物;所述防晒剂为奥克立林、胡莫柳酯、丁基甲氧基二苯甲酰基甲烷、生育酚类和向日葵籽油的复配物。
本发明的目的之三采用如下技术方案实现:
一种新的护肤霜的制备方法,包括以下步骤:
将配方量的溶剂、保湿剂、防晒剂、美白亮肤调理剂、防护调理剂和修复调理剂加入乳化锅中,搅拌均匀,得到混合物1;
将配方量的润肤剂、抗氧剂、螯合剂投入所述乳化锅中,搅拌均匀,升温至35-45℃,得到混合物2;
将配方量的乳化剂和增稠剂投入所述乳化锅中,将体系维持在35-45℃下,乳化0.5-1.5h,得到混合物3;
将体系降温至20-30℃,继续搅拌1.5-2.5h,得到混合物4;
取样检测,理化指标及稳定性合格后,放真空,出料,即得。
相比现有技术,本发明的有益效果在于:
(1)本发明所提供的美白亮肤的皮肤调理剂复合物由美白亮肤调理剂、防护调理剂和修复调理剂组成,具体成分包括美白原料、天然原料以及中药复配物,这些组分协同作用,能够同时实现美白、防护及修复三重功能。
(2)本发明所提供的新的护肤霜,以美白亮肤调理剂、防护调理剂和修复调理剂为活性成分,具体成分包括美白原料、天然原料以及中药复配物,这些组分协同作用,能够同时实现美白、防护及修复三重功能。
(3)本发明所提供的新的护肤霜的制备方法,流程简便,对设备、操作人员要求不高,便于实现工业化生产。
附图说明
图1为本发明斑马鱼实验中的结果图;
图2为本发明豚鼠实验中的拍照结果图;
图3为本发明豚鼠实验中组织学观察的结果图;
图4为本发明保湿功效测试中的水分含量变化图。
具体实施方式
下面,结合附图以及具体实施方式,对本发明做进一步描述,需要说明的是,在不相冲突的前提下,以下描述的各实施例之间或各技术特征之间可以任意组合形成新的实施例。在下述实施例中所采用的原材料、设备等除特殊限定外均可以通过购买方式获得。
本发明实施例所用到的原料药可从市场购买得到,各成分均在在《2021版化妆品原料目录》中,其标准符合国家及企业相关要求。
一种美白亮肤的皮肤调理剂复合物,包括按照重量份剂的以下组分:美白亮肤调理剂2-8份,防护调理剂2-8份,修复调理剂0.0005-1份;美白亮肤调理剂包括烟酰胺、己基间苯二酚和肌肽;防护调理剂包括VC乙基醚、尿囊素、甘草酸二钾、提取复配物canlmyang、富勒烯、纳米金和红没药醇;修复调理剂包括提取复配物百倍舒。
本发明实施例所提供的美白亮肤的皮肤调理剂复合物由美白亮肤调理剂、防护调理剂和修复调理剂组成,具体成分包括美白原料、天然原料以及中药复配物,这些组分协同作用,能够同时实现美白、防护及修复三重功能,具体地:
美白亮肤调理剂:
VB3(烟酰胺)、白肽美肤剂(己基间苯二酚)和玉肌灵(肌肽)复配,起到美白、保湿和抗衰作用。
防护调理剂:
VC乙基醚:进入真皮层后直接参与胶原蛋白的合成,修复皮肤,增强细胞活性,使胶原蛋白增加,从而使皮肤变得充盈富有弹性,使肌肤细腻光滑,还有抑制酪氨酸酶形成,具有美白抗氧化作用;
尿囊素:减轻肌肤的局部充血,改善过敏,修复皮肤屏障的作用;
甘草酸二钾:有抗炎、抗过敏、保湿等功效;
提取复配物canlmyang:具有防护的效果;
富勒烯:亲和自由基,具有抗氧化作用;
纳米金:本发明实施例所采用的纳米金包含银耳多糖成分,能够与大生物大分子结合,具有抗衰的功效;
红没药醇:a-红没药醇具有很好的稳定性及很好的皮肤相容性,不仅具有抗炎性能,还被证明有抑菌活性。
修复调理剂:
提取复配物百倍舒:修复型中药材提取物复配,有很好的抑菌、消炎效果,起到皮肤防护修复作用。
作为优选的实施方式,提取复配物canlmyang为积雪草提取物、虎杖提取物、黄芩提取物、茶叶提取物、光果甘草提取物、母菊花提取物和迷迭香叶提取物形成的复配物,具有很好地防护的效果。
作为优选的实施方式,提取复配物百倍舒为黄柏提取物、蛇床子提取物、五倍子提取物、金黄洋甘菊提取物、积雪草提取物、甘草类黄酮和冰片形成的复配物,有很好的抑菌、消炎效果,起到皮肤防护作用。
作为优选的实施方式,美白亮肤调理剂还包括表面活性剂和抗菌剂,更加优选地表面活性剂和抗菌剂为二辛基醚、亚油酸和苯氧乙醇的复配物(又称为素颖亮肤剂),能够避免皮肤干涩,维持皮肤油性。
作为优选的实施方式,防护调理剂还包括生物缓冲剂,更加优选地,生物缓冲剂为羟乙基哌嗪乙烷磺酸和水的复配物,其作为氢离子缓冲剂,能够控制产品在恒定的pH范围。
作为优选的实施方式,美白亮肤调理剂包括烟酰胺1-3.5份、己基间苯二酚0.25-1份、肌肽0.1-0.3份、表面活性剂和抗菌剂1-3份,各组分用量合理设置,发挥最大的美白、保湿和抗衰作用。
作为优选的实施方式,防护调理剂包括VC乙基醚0.5-3份、尿囊素0.1-1份、甘草酸二钾0.1-1份、提取复配物canlmyang0.05-0.1份、生物缓冲剂0.3-0.8份、富勒烯0.00001-0.0001份、纳米金0.00005-0.0001份和红没药醇0.1-1份,各组分用量合理设置,发挥最大的防护功效。
作为优选的实施方式,修复调理剂包括提取复配物百倍舒0.0005-0.001份。
本发明实施例所提供的美白亮肤的皮肤调理剂复合物,能够同时实现美白、防护及修复三重功能。该美白亮肤的皮肤调理剂复合物作为活性成分可以用于多种类型的护肤品、化妆品中,例如新的护肤霜、护肤水、精华液、面膜等,根据实际的产品类型与相应的辅料、或其他功能性成分复配即可。
本发明实施例又公开了一种集亮肤与防护功能为一体的新的护肤霜,是一种含有美白、保湿、抗氧化、抗衰及皮肤护理功效为一体的配方,通过实验功效实验验证,消费者使用反馈,有效率90%以上,满意率95%。具体方案如下。
一种新的护肤霜,包括由美白亮肤调理剂、防护调理剂和修复调理剂为活性成分的美白亮肤的皮肤调理剂复合物。
作为优选的实施方式,新的护肤霜包括按照重量份计的以下组分:溶剂50-70份;保湿剂10-20份;润肤剂5-15份;增稠剂1.5-8份;乳化剂1.5-8份;防晒剂0.1-1份;抗氧剂0.1-1份;螯合剂0.01-0.5份;美白亮肤调理剂2-8份,防护调理剂2-8份,修复调理剂0.0005-1份。
作为优选的实施方式,溶剂包括水;保湿剂包括丁二醇、甘油聚醚-26、己二醇、乳酸和木糖醇复配保湿剂;润肤剂包括植物角鲨烷和聚二甲基硅氧烷;增稠剂包括鲸蜡硬脂醇、汉生胶、ZEN增稠剂和G57增稠剂;乳化剂包括硬脂醇聚醚-2和硬脂醇聚醚-21;抗氧剂包括对羟基苯乙酮(又称馨鲜酮);螯合剂包括EDTA-2NA。
作为优选的实施方式,ZEN增稠剂为聚丙烯酸酯交联聚合物-6、叔丁醇和水形成的复配物。
作为优选的实施方式,木糖醇复配保湿剂为木糖醇基葡糖苷、脱水木糖醇、木糖醇和葡萄糖的复配物,又称为AQUAXYL木糖醇复配保湿剂,具有保湿效果。
作为优选的实施方式,G57增稠剂为聚丙烯酸钠、C18-21烷和十三烷醇聚醚-6的复配物。
作为优选的实施方式,防晒剂为奥克立林、胡莫柳酯、丁基甲氧基二苯甲酰基甲烷、生育酚类和向日葵籽油的复配物,此复合防晒剂又称为PARSOL Guard护色剂。
本发明实施例所提供的新的护肤霜,其他功能辅料如润肤剂、增稠剂及螯合剂等,能够增强配方成型,保持配方的稳定性。
本发明实施例所提供的新的护肤霜,申请人将其称为“雪之颜亮肤霜”,其是根据黄种人的皮肤特点,依据皮肤代谢衰老的特点进行设计的,经受试者使用后,反馈良好。此新的护肤霜是一种基于中西医结合思想形成的组方,既包含化妆品美白防晒成分,也包含中药植物提取物形成的防护与修复复配液,最终形成了一种美白、防护与修复功能于一体的新型功效护肤品。该配方解决了常规护肤品采用单一化学成分进行美白的缺点,从多方面、多个通道保养皮肤,使皮肤焕发年轻态。
一种新的护肤霜的制备方法,包括以下步骤:
将配方量的溶剂、保湿剂、防晒剂、美白亮肤调理剂、防护调理剂和修复调理剂加入乳化锅中,搅拌15-25分钟,搅拌均匀,得到混合物1;
将配方量的润肤剂、抗氧剂、螯合剂投入乳化锅中,搅拌均匀,升温至35-45℃,得到混合物2;
将配方量的乳化剂和增稠剂投入乳化锅中,将体系维持在35-45℃下,乳化0.5-1.5h,得到混合物3;
将体系降温至20-30℃,继续搅拌1.5-2.5h,得到混合物4;
取样检测,理化指标及稳定性合格后,放真空,出料,微检合格后灌装;
包装后再抽检成品,合格后入库。
实施例1
一种新的护肤霜,由溶剂、保湿剂、润肤剂、增稠剂、乳化剂、防晒剂、抗氧剂、螯合剂、美白亮肤调理剂、防护调理剂和修复调理剂制备而成。具体配方如下表1所示。
表1实施例1新的护肤霜的配方表
实施例1的新的护肤霜按照以下方法制备而成:
将配方量的溶剂、保湿剂、防晒剂、美白亮肤调理剂、防护调理剂和修复调理剂加入乳化锅中,搅拌20分钟,搅拌均匀,得到混合物1;
将配方量的润肤剂、抗氧剂、螯合剂投入乳化锅中,搅拌均匀,升温至40℃,得到混合物2;
将配方量的乳化剂和增稠剂投入乳化锅中,将体系维持在40℃下,乳化1h,得到混合物3;
将体系降温至25℃,继续搅拌2h,得到混合物4;
取样检测,理化指标及稳定性合格后,放真空,出料,微检合格后灌装;
包装后再抽检成品,合格后入库。
实施例2
实施例2与实施例1的不同之处在于:美白亮肤调理剂的用量不同,其余与实施例1相同,美白亮肤调理剂的组成如下表2所示。
表2实施例2美白亮肤调理剂的配方表
实施例3
实施例3与实施例1的不同之处在于:美白亮肤调理剂的用量不同,其余与实施例1相同,美白亮肤调理剂的组成如下表3所示。
表3实施例3美白亮肤调理剂的配方表
实施例4
实施例4与实施例1的不同之处在于:美白亮肤调理剂的用量不同,其余与实施例1相同,美白亮肤调理剂的组成如下表4所示。
表4实施例4美白亮肤调理剂的配方表
对比例1
对比例1与实施例1的不同之处在于:不包含美白亮肤调理剂,其余与实施例1相同。
对比例2
对比例2与实施例1的不同之处在于:不包含防护调理剂,其余与实施例1相同。
对比例3
对比例3与实施例1的不同之处在于:不包含修复调理剂,其余与实施例1相同。
效果评价
一、斑马鱼模型
斑马鱼作为模式生物用于评价实验的优势在于:个体小,占空间少,易于饲养,成本较低,可进行大规模筛选实验;繁殖能力强,全年产卵且数量大,利于统计分析;斑马鱼也是几个特定的基因控制着黑素生成、相关细胞的发育调节。例如SOX10控制小眼相关转录因子(MITF)的转录,MITF是黑素生成相关酶的表达调节因子,包括酪氨酸酶、TRP-1、TRP-2和Pmel。黑色素的形成、转运和代谢是美白祛斑化妆品研究开发的重点,斑马鱼胚胎模型身体表面本身有黑素沉淀,可直接用于黑素抑制效应的评价,可大大简化美白活性成分和美白产品的功效评价实验过程。
1、实验方案:
样品来源
对照组:1-苯基-2-硫脲(DZ)。
亮肤霜:本发明实施例1-4的样品,分别记为LFS-1实施例1;LFS-2实施例2、LFS-3实施例3、LFS-4实施例4。
2、斑马鱼拍照
C:为空白模型组;
DZ:1-苯基-2-硫脲,阳性对照。
LFS:本发明实施例1-4的样品(LFS)。
3、试验结果
每个组别处理斑马鱼胚胎72h,进行拍照,然后测量黑素生成的水平,结果如图1所示,图中DZ代表阳性对照组,1-苯基-2-硫脲的浓度分别为1μmol/L、10μmol/L和100μmol/L;图中LFS代表实验组,分别使用本发明实施例1-4样品(添加不同浓度美白亮肤成分)。
4、结论
从图1中可看出,本发明实施例1-4所提供的样品具有美白效果。
二、豚鼠皮肤模型
以棕色成年豚鼠为实验动物,分别选取背部皮肤部位后脱毛,用UVB紫外照射,UVB紫外灯管照射波长为310nm,持续2天诱导相应部位皮肤色素沉着。
1、试验设计:
A:空白模型组;
B:白藜芦醇膏剂,对照组;
C:本发明实施例1的样品,实验组。
分别将对照组样品和实验组样品涂于实验动物背部的去毛皮肤上,坚持每日涂敷产品,并设空白模型组。经过7天照射结果,建立模型,取豚鼠的皮肤活组织切片染色后,进行组织学观察,显微照相,并对其进行光密度分析,对基底细胞中含黑素颗粒细胞计数及多巴阳性细胞计数进行比较。
2、试验结果:
采用棕色豚鼠UVB照射诱导色素沉着后,将模型组分为两组(对照组、实验组),对照组每天涂白藜芦醇膏剂,实验组每天涂实施例1的样品,持续14d,结果显示对照组(白藜芦醇)和实施例1样品均降低了UVB诱导的皮肤色素过度沉着。14天后,空白模型组的黑色素沉着指数为62.6±2.3,对照组的皮肤中色素指数降低至53.4±1.0,而实验组的皮肤中色素指数为40.7±1.6。如图2所示,为豚鼠背部脱毛皮肤经过UVB紫外照射后,3个组别分别进行不同处理后的结果图(空白模型组不做任何处理,对照组涂白藜芦醇膏剂14d,实验组涂本发明实施例1样品14d),图2A为空白模型组的结果图,图2B为对照组的结果图,图2C为实验组的结果图。
采用棕色豚鼠UVB照射诱导色素沉着后,对照组每天涂白藜芦醇膏剂,实验组每天涂实施例1的样品,持续14d后,取豚鼠的皮肤活组织切片,通过Fontana-Masson染色后进行组织学观察,评估皮肤组织中的黑素生成。如图3所示,图3A为空白模型组的结果图,图3B为对照组的结果图,图3C为实验组的结果图,从图中可得,使用本发明实施例1的样品后,降低了皮肤黑素的产生,可见,本发明实施例所提供的新的护肤霜具有美白效果。
三、保湿功效测试
保湿是化妆品的基础功效,目前我国评价化妆品保湿功效时,常依据《QB-T4256-2011化妆品保湿功效评价指南》进行评价,本次测试选取25名志愿者,试验时间为2020年10月17日-2020年11月13日,受试者平均年龄为40±2岁。
1、试验设计
根据试验结果,通过软件生成随机数字,实验组一侧脸颊使用实施例1样品,另一侧脸颊按日常方法洁面(对照组)。受试者使用测试样品前、使用后1h、3h、6h进行短期保湿观察,短期保湿产品用量为0.3g/半脸;在使用测试产品前、使用后第7d、第14d进行长期保湿观察,长期保湿产品用量为0.1/半脸。测试期间禁止使用其他同类产品。
2、测试项目
使用皮肤角质层水分含量测量仪测量左、右脸颊部位角质层水分含量。
使用经皮失水率测量仪测量左、右脸颊部位的皮肤经表皮失水率,测量3次取平均值。
3、试验结果
图4为皮肤水分含量测试结果图,由图4可知,实验组与对照组在使用样品前皮肤水分含量值最低,分别为(55.68±1.72)AU、(56.06±1.65)AU,两者间无显著性差异。实验组单次使用亮肤霜1h、3h、6h,皮肤水分含量值均呈现升高趋势,分别为20.30%、25.66%和32.12%(详见表5)。
与对照组相比,实验组受试者在单次使用亮肤霜后7d、14d的经表皮失水率值的变化率降低更多,差异具有统计学意义(p<0.001)。
表5保湿功效测试结果记录表(数据取平均值)
1h | 3h | 6h | 7d | 14d | |
对照组 | 55.72 | 55.84 | 55.81 | 55.77 | 55.74 |
实验组 | 76.02 | 81.50 | 87.93 | 101.43 | 101.82 |
差值 | 20.30 | 25.66 | 32.12 | 45.66 | 46.08 |
结果表明,实施例1的样品具有很好的保湿效果。
四、志愿者使用实验
选取50名女性消费者,这些消费者均有皮肤暗黄、敏感肌、痘印、出油的症状,分别使用对照组(贵妇膏)、实验组(实施例1)和对比例1-3样品,跟踪各位消费者的使用情况,进行数据统计。
1、试验方案:
按照要求分组:对照组5人、实验组30人(分两组,每组15人)、对比例1-3均分别为5人。
样品来源:
对照组:购买于市场美白产品贵妇膏;
实验组:本发明实施例1样品;
对比例1:对比例1样品;
对比例2:对比例2样品;
对比例3:对比例3样品。
2、试验结果
表6中的数据为有效数据,例如实验一组中的亮白13,说明15名志愿者中13人认为有亮白功效。
表6适应症及效果反馈统计
3、结论:
通过跟踪消费者并进行结果统计,对照品具有美白、轻微防护效果,没有修护作用。而使用实施例1样品的30名使用者中,具有明显美白27名,有效率90%;防护30名,有效率100%;修护26名,有效率86.7%。结果证明本发明实施例1的样品具有很好美白、防护及修复效果,比同类上市产品更好效果。
对比例1的样品相比实施例1的样品缺了美白亮肤调理剂,亮白功效为0,防护有效率为60%,修复有效率为60%。可见,样品中缺了美白亮肤调理剂,不但亮白功效消失,防护和修复效果都会下降,说明了本发明实施例中的美白亮肤调理剂、防护调理剂和修复调理剂是协同生效的,三者共存会提升亮白、防护和修复效果。
对比例2的样品相比实施例1的样品缺了防护调理剂,防护功效为0,亮白有效率为80%,修护有效率为60%。可见,样品中缺了防护调理剂,不但防护功效消失,亮白和修复效果都会下降,说明了本发明实施例中的美白亮肤调理剂、防护调理剂和修复调理剂是协同生效的,三者共存会提升亮白、防护和修复效果。
对比例3的样品相比实施例1的样品缺了修复调理剂,修护功效为0,亮白有效率为80%,防护有效率为60%。可见,样品中缺了修复调理剂,不但修复功效消失,亮白和防护效果都会下降,说明了本发明实施例中的美白亮肤调理剂、防护调理剂和修复调理剂是协同生效的,三者共存会提升亮白、防护和修复效果。
上述实施方式仅为本发明的优选实施方式,不能以此来限定本发明保护的范围,本领域的技术人员在本发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (10)
1.一种美白亮肤的皮肤调理剂复合物,其特征在于,包括按照重量份剂的以下组分:美白亮肤调理剂2-8份,防护调理剂2-8份,修复调理剂0.0005-1份;所述美白亮肤调理剂包括烟酰胺、己基间苯二酚和肌肽;所述防护调理剂包括VC乙基醚、尿囊素、甘草酸二钾、提取复配物canlmyang、富勒烯、纳米金和红没药醇;所述修复调理剂包括提取复配物百倍舒。
2.如权利要求1所述的美白亮肤的皮肤调理剂复合物,其特征在于,所述提取复配物canlmyang为积雪草提取物、虎杖提取物、黄芩提取物、茶叶提取物、光果甘草提取物、母菊花提取物和迷迭香叶提取物形成的复配物;所述提取复配物百倍舒为黄柏提取物、蛇床子提取物、五倍子提取物、金黄洋甘菊提取物、积雪草提取物、甘草类黄酮和冰片形成的复配物。
3.如权利要求1所述的美白亮肤的皮肤调理剂复合物,其特征在于,所述美白亮肤调理剂还包括表面活性剂和抗菌剂;所述防护调理剂还包括生物缓冲剂。
4.如权利要求3所述的美白亮肤的皮肤调理剂复合物,其特征在于,所述表面活性剂和抗菌剂为二辛基醚、亚油酸和苯氧乙醇的复配物;所述生物缓冲剂为羟乙基哌嗪乙烷磺酸和水的复配物。
5.如权利要求1所述的美白亮肤的皮肤调理剂复合物,其特征在于,所述美白亮肤调理剂包括烟酰胺1-3.5份、己基间苯二酚0.25-1份、肌肽0.1-0.3份、表面活性剂和抗菌剂1-3份;
所述防护调理剂包括VC乙基醚0.5-3份、尿囊素0.1-1份、甘草酸二钾0.1-1份、提取复配物canlmyang0.05-0.1份、生物缓冲剂0.3-0.8份、富勒烯0.00001-0.0001份、纳米金0.00005-0.0001份和红没药醇0.1-1份;
所述修复调理剂包括提取复配物百倍舒0.0005-0.001份。
6.一种新的护肤霜,其特征在于,包括权利要求1-5任一项所述的美白亮肤的皮肤调理剂复合物。
7.如权利要求6所述的新的护肤霜,其特征在于,所述新的护肤霜包括按照重量份计的以下组分:溶剂50-70份;保湿剂10-20份;润肤剂5-15份;增稠剂1.5-8份;乳化剂1.5-8份;防晒剂0.1-1份;抗氧剂0.1-1份;螯合剂0.01-0.5份;美白亮肤调理剂2-8份,防护调理剂2-8份,修复调理剂0.0005-1份。
8.如权利要求7所述的新的护肤霜,其特征在于,所述溶剂包括水;所述保湿剂包括丁二醇、甘油聚醚-26、己二醇、乳酸和木糖醇复配保湿剂;所述润肤剂包括植物角鲨烷和聚二甲基硅氧烷;所述增稠剂包括鲸蜡硬脂醇、汉生胶、聚丙烯酸酯交联聚合物-6和G57增稠剂;所述乳化剂包括硬脂醇聚醚-2和硬脂醇聚醚-21;所述抗氧剂包括对羟基苯乙酮;所述螯合剂包括EDTA-2NA。
9.如权利要求8所述的新的护肤霜,其特征在于,所述木糖醇复配保湿剂为木糖醇基葡糖苷、脱水木糖醇、木糖醇和葡萄糖的复配物;所述G57增稠剂为聚丙烯酸钠、C18-21烷和十三烷醇聚醚-6的复配物;所述防晒剂为奥克立林、胡莫柳酯、丁基甲氧基二苯甲酰基甲烷、生育酚类和向日葵籽油的复配物。
10.一种如权利要求7-9任一项所述的新的护肤霜的制备方法,其特征在于,包括以下步骤:
将配方量的溶剂、保湿剂、防晒剂、美白亮肤调理剂、防护调理剂和修复调理剂加入乳化锅中,搅拌均匀,得到混合物1;
将配方量的润肤剂、抗氧剂、螯合剂投入所述乳化锅中,搅拌均匀,升温至35-45℃,得到混合物2;
将配方量的乳化剂和增稠剂投入所述乳化锅中,将体系维持在35-45℃下,乳化0.5-1.5h,得到混合物3;
将体系降温至20-30℃,继续搅拌1.5-2.5h,得到混合物4;
取样检测,理化指标及稳定性合格后,放真空,出料,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110942740.7A CN113440468A (zh) | 2021-08-17 | 2021-08-17 | 美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110942740.7A CN113440468A (zh) | 2021-08-17 | 2021-08-17 | 美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113440468A true CN113440468A (zh) | 2021-09-28 |
Family
ID=77818512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110942740.7A Pending CN113440468A (zh) | 2021-08-17 | 2021-08-17 | 美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113440468A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113917130A (zh) * | 2021-10-11 | 2022-01-11 | 青蛙王子(福建)婴童护理用品有限公司 | 利用斑马鱼评价婴童化妆品眼刺激的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619033A (zh) * | 2018-07-05 | 2018-10-09 | 上海新高姿化妆品有限公司 | 具有协同美白效果的美白护肤精华及其制备方法 |
CN109528603A (zh) * | 2019-01-23 | 2019-03-29 | 上海彤颜实业有限公司 | 美白组合物、包含美白组合物的美白亮肤霜及其制备方法 |
CN111281840A (zh) * | 2020-02-13 | 2020-06-16 | 广州伊尔美生物科技有限公司 | 一种亮颜美肤霜及其制备方法 |
CN111743796A (zh) * | 2020-05-26 | 2020-10-09 | 泉后(广州)生物科技研究院有限公司 | 一种美白乳及其制备方法 |
CN113244144A (zh) * | 2021-06-07 | 2021-08-13 | 广州黛莱美化妆品有限公司 | 一种提亮肤色的面霜 |
-
2021
- 2021-08-17 CN CN202110942740.7A patent/CN113440468A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619033A (zh) * | 2018-07-05 | 2018-10-09 | 上海新高姿化妆品有限公司 | 具有协同美白效果的美白护肤精华及其制备方法 |
CN109528603A (zh) * | 2019-01-23 | 2019-03-29 | 上海彤颜实业有限公司 | 美白组合物、包含美白组合物的美白亮肤霜及其制备方法 |
CN111281840A (zh) * | 2020-02-13 | 2020-06-16 | 广州伊尔美生物科技有限公司 | 一种亮颜美肤霜及其制备方法 |
CN111743796A (zh) * | 2020-05-26 | 2020-10-09 | 泉后(广州)生物科技研究院有限公司 | 一种美白乳及其制备方法 |
CN113244144A (zh) * | 2021-06-07 | 2021-08-13 | 广州黛莱美化妆品有限公司 | 一种提亮肤色的面霜 |
Non-Patent Citations (1)
Title |
---|
电子凭证-国产非特殊用途化妆品备案信息服务平台: "春之唤雪之颜亮肤霜[升级版]", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20210105201952Y3OP1&NID=20210105201952Y3OP1》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113917130A (zh) * | 2021-10-11 | 2022-01-11 | 青蛙王子(福建)婴童护理用品有限公司 | 利用斑马鱼评价婴童化妆品眼刺激的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108403521A (zh) | 局部皮肤用组合物及其用途 | |
CN106176348A (zh) | 局部皮肤用组合物及处理皮肤的方法 | |
KR101928797B1 (ko) | 컴파운드 k를 함유하는 피부 외용제 조성물 | |
TW200904482A (en) | Compositions and methods for inhibiting melanogenesis | |
US20130101689A1 (en) | Composition containing paper mulberry extracts | |
US7189419B2 (en) | Use of active extracts to lighten skin, lips, hair, and/or nails | |
CN109771351A (zh) | 一种美白淡斑组合物及其应用 | |
US10406096B2 (en) | Compositions comprising extracts of Bursera simaruba | |
WO2024109386A1 (zh) | 促渗增效的美白组合物 | |
CN113440468A (zh) | 美白亮肤的皮肤调理剂复合物、新的护肤霜及其制备方法 | |
CN112294739A (zh) | 一种多效美白组合物及其在润肤霜中的应用 | |
KR101939112B1 (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 | |
KR101954632B1 (ko) | 발아 인삼씨 추출물을 함유하는 피부 외용제 조성물 | |
KR20140126891A (ko) | 진세노사이드 Rf를 함유하는 피부 외용제 조성물 | |
KR20130115482A (ko) | 발아 녹차씨 추출물을 함유하는 피부 외용제 조성물 | |
KR101909533B1 (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 | |
CN112618422A (zh) | 复合美白组合物、制备方法及用途 | |
KR101910865B1 (ko) | 발아 인삼씨 추출물을 함유하는 피부 외용제 조성물 | |
KR101945204B1 (ko) | 발아 인삼씨 추출물을 함유하는 피부 외용제 조성물 | |
KR102246930B1 (ko) | 상백피 및 호장근의 복합추출물과 마누카꿀을 포함하는 화장료 조성물 | |
US10835470B2 (en) | Cosmetics composition containing ginsenoside as active ingredient | |
CN114246820A (zh) | 一种晚霜的组成 | |
CN118370709A (zh) | 美白组合物 | |
CN116056684A (zh) | 包含白术内酯-i或白术内酯-i的源的个人护理组合物 | |
CN111249323A (zh) | 艾叶提取物及其在皮肤外用剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210928 |